RegenLab USA, which provides medical devices for tissue repair and other regenerative medicinal uses, announced terms for its IPO on Tuesday.
The Jersey City, NJ-based company plans to raise $18 million by offering 2.5 million shares at a price range of $6 to $8. At the midpoint of the proposed range, RegenLab USA would command a fully diluted market value of $157 million.
RegenLab develops and manufactures single-use devices that prepare autologous platelet-rich plasma (PRP), alone or combined with hyaluronic acid (HA), at the point of care. Its products are used in musculoskeletal, wound care, aesthetic, and women's health settings. The company's two main products are RegenKit, a PRP preparation kit, and Cellular Matrix, a PRP-HA combination for knee osteoarthritis. Most products are CE-marked in Europe, and several RegenKit configurations, including a wound gel covered by Medicare, are FDA-cleared in the US. Cellular Matrix is not yet approved in the US and remains in the PMA process. Founded in Switzerland in 2003, the company runs manufacturing sites in Switzerland, France, and New Jersey, and sells through direct sales forces and distributors in about 90 countries.
RegenLab USA was founded in 2003 and booked $54 million in revenue for the 12 months ended June 30, 2026. It plans to list on the Nasdaq under the symbol RGNA. StoneX Financial is the sole bookrunner on the deal.
